Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.
Wenning LA, Petry AS, Kost JT, Jin B, Breidinger SA, DeLepeleire I, Carlini EJ, Young S, Rushmore T, Wagner F, Lunde NM, Bieberdorf F, Greenberg H, Stone JA, Wagner JA, Iwamoto M. Wenning LA, et al. Among authors: delepeleire i. Clin Pharmacol Ther. 2009 Jun;85(6):623-7. doi: 10.1038/clpt.2009.12. Epub 2009 Mar 11. Clin Pharmacol Ther. 2009. PMID: 19279563 Clinical Trial.
In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.
Tang C, Shou M, Rushmore TH, Mei Q, Sandhu P, Woolf EJ, Rose MJ, Gelmann A, Greenberg HE, De Lepeleire I, Van Hecken A, De Schepper PJ, Ebel DL, Schwartz JI, Rodrigues AD. Tang C, et al. Pharmacogenetics. 2001 Apr;11(3):223-35. doi: 10.1097/00008571-200104000-00006. Pharmacogenetics. 2001. PMID: 11337938
Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers.
Majumdar AK, Howard L, Goldberg MR, Hickey L, Constanzer M, Rothenberg PL, Crumley TM, Panebianco D, Bradstreet TE, Bergman AJ, Waldman SA, Greenberg HE, Butler K, Knops A, De Lepeleire I, Michiels N, Petty KJ. Majumdar AK, et al. J Clin Pharmacol. 2006 Mar;46(3):291-300. doi: 10.1177/0091270005283467. J Clin Pharmacol. 2006. PMID: 16490805 Clinical Trial.
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA. Herman GA, et al. J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. doi: 10.1210/jc.2006-1009. Epub 2006 Aug 15. J Clin Endocrinol Metab. 2006. PMID: 16912128 Clinical Trial.
Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist.
Lai E, Wenning LA, Crumley TM, De Lepeleire I, Liu F, de Hoon JN, Van Hecken A, Depré M, Hilliard D, Greenberg H, O'Neill G, Metters K, Gottesdiener KG, Wagner JA. Lai E, et al. Clin Pharmacol Ther. 2008 Jun;83(6):840-7. doi: 10.1038/sj.clpt.6100345. Epub 2007 Sep 19. Clin Pharmacol Ther. 2008. PMID: 17882161 Clinical Trial.
Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
Addy C, Rothenberg P, Li S, Majumdar A, Agrawal N, Li H, Zhong L, Yuan J, Maes A, Dunbar S, Cote J, Rosko K, Van Dyck K, De Lepeleire I, de Hoon J, Van Hecken A, Depré M, Knops A, Gottesdiener K, Stoch A, Wagner J. Addy C, et al. J Clin Pharmacol. 2008 Jun;48(6):734-44. doi: 10.1177/0091270008317591. J Clin Pharmacol. 2008. PMID: 18508950 Clinical Trial.
75 results